180253-65-0

Basic information

• Product Name: Carbamic acid, (3-methyl-4-pyridinyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-methyl-4-pyridinyl)-, 1,1-dimethylethyl ester (9CI);tert-butyl N-(3-methylpyridin-4-yl)carbamate
• CAS NO: 180253-65-0
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.25694
• Product Categories: N-BOC
• Mol File: 180253-65-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, (3-methyl-4-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-methyl-4-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(180253-65-0)
• EPA Substance Registry System: Carbamic acid, (3-methyl-4-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(180253-65-0)

Safety Data

• Hazardous Substances Data: 180253-65-0(Hazardous Substances Data)

Upstream product

• 98400-69-2 N-(4-pyridyl) t-butyl carbamate 
• 74-88-4 methyl iodide 
• 1990-90-5 4-amino-3-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1074-98-2 3-methyl-4-nitropyridine N-oxide 

Downstream Products

• 264883-49-0 2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5-azaindole 
• 264883-50-3 methyl 2-Methoxy-4-[[2-[4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]-5-azaindol-1-yl]methyl]benzoate 
• 264883-44-5 1-[3-methoxy-4-(1-pyrrolidinylmethyl)benzyl]-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5-azaindole 
• 264883-42-3 1-[3-methoxy-4-(1-pyrrolidinylcarbonyl)benzyl]-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5-azaindole 
• 271-34-1 5-azaindole 
• 37388-07-1 2-phenyl-1H-pyrrolo[3,2-c]pyridine 
• 849777-09-9 [2-(5-chloro-2-fluoro-phenyl)-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-pyridin-4-yl)-carbamic acid tert-butyl ester 

Relevant articles and documents

HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE

Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

TETRAHYDROISOQUINOLINE DERIVATIVES

The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), wherein G represents a fused heterocyclic system selected from the groups represented by formula (G1), (G2), (G3), (G4/sup

ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS

The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A1 and A2 represent direct bond or C(=O), with the proviso that 0 or 1 of A1 and A2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R1 denotes H, F, CI, Br, I, CN, CF3, CF2H, CFH2, CO2H, CO2R13, R13, OH. O-R13, NH2, N(H)R13, N(R13)2, R2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF3, CF2H, CFH2, R13, OH, O-R13, NH2, N(H)R13 and N(R13)2; Ar1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF3. CF2H, CFH2, R13 and O- R13; or C3-6-cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.